Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Institute of Pathology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
BJU Int. 2024 Aug;134(2):249-257. doi: 10.1111/bju.16298. Epub 2024 Feb 26.
To develop a prognostically relevant scoring system for stage pT1 non-muscle-invasive bladder cancer (NMIBC) incorporating tumour budding, growth pattern and invasion pattern because the World Health Organisation grading system shows limited prognostic value in such patients.
The tissue specimens and clinical data of 113 patients with stage pT1 NMIBC who underwent transurethral resection of bladder tumour were retrospectively investigated. Tumour budding, and growth and invasion patterns were evaluated and categorised into two grade groups (GGs). GGs and other clinical and histopathological variables were investigated regarding recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS) using univariable and multivariable Cox regression analyses.
The integration of two tumour budding groups, two growth patterns, and two invasion patterns yielded an unfavourable GG (n = 28; 24.7%) that had a high impact on oncological outcomes. The unfavourable GG was identified as an independent RFS and OS predictor (P = 0.004 and P = 0.046, respectively) and linked to worse PFS (P = 0.001) and CSS (P = 0.001), irrespective of the European Association of Urology risk group. The unfavourable GG was associated with higher rates of BCG-unresponsive tumours (P = 0.006). Study limitations include the retrospective, single-centre design, diverse therapies and small cohort.
We present a morphology-based grading system for stage pT1 NMIBC that correlates with disease aggressiveness and oncological patient outcomes. It therefore identifies a highest risk group of stage pT1 NMIBC patients, who should be followed up more intensively or receive immediate radical cystectomy. The grading incorporates objective variables assessable on haematoxylin and eosin slides and immunohistochemistry, enabling an easy-to-use low-cost approach that is applicable in daily routine. Further studies are needed to validate and confirm these results.
建立一个与肿瘤芽生、生长模式和浸润模式相关的、用于预测 pT1 期非肌层浸润性膀胱癌(NMIBC)患者预后的评分系统,因为世界卫生组织(WHO)分级系统在这些患者中的预后价值有限。
回顾性分析 113 例接受经尿道膀胱肿瘤切除术的 pT1 期 NMIBC 患者的组织标本和临床资料。评估肿瘤芽生情况,并对生长模式和浸润模式进行分类,分为两个等级组(GG)。使用单变量和多变量 Cox 回归分析,评估 GG 及其他临床和组织病理学变量与无复发生存(RFS)、无进展生存(PFS)、癌症特异性生存(CSS)和总生存(OS)的关系。
将两个肿瘤芽生组、两种生长模式和两种浸润模式相结合,得到一个预后不良的 GG(n=28;24.7%),该 GG 对肿瘤的预后有显著影响。预后不良的 GG 是 RFS 和 OS 的独立预测因素(P=0.004 和 P=0.046),与较差的 PFS(P=0.001)和 CSS(P=0.001)相关,与欧洲泌尿外科学会(EAU)风险组无关。预后不良的 GG 与卡介苗无反应肿瘤的发生率较高有关(P=0.006)。研究局限性包括回顾性、单中心设计、不同的治疗方法和小样本量。
我们提出了一种基于形态学的 pT1 期 NMIBC 分级系统,该系统与疾病侵袭性和肿瘤患者的预后相关。它因此确定了一个 pT1 期 NMIBC 患者的最高风险组,这些患者应更密切地随访或立即接受根治性膀胱切除术。该分级系统纳入了在苏木精和伊红染色切片及免疫组织化学上可评估的客观变量,能够实现一种易于使用、成本低廉的方法,适用于日常实践。需要进一步的研究来验证和确认这些结果。